20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MBX Biosciences, Inc. Common Stock (MBX) operates in the BIOTECHNOLOGY industry and is headquartered in Carmel, United States with about 63 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, MBX reported $0M in revenue and ($87M) in net income.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — |
| Operating Income (EBIT) | ($118M) | ($98M) | ($68M) | ($35M) | ($25M) |
| Operating Margin % | — | — | — | — | — |
| Net Income | ($104M) | ($87M) | ($62M) | ($33M) | ($26M) |
| Net Margin % | — | — | — | — | — |
| EBITDA | ($108M) | ($87M) | ($62M) | ($32M) | ($26M) |
| Earnings Per Share (EPS) | $-2.52 | $-2.38 | $-1.85 | $-1.02 | $-0.82 |
| Shares Outstanding (M) | 48M | 37M | 33M | 32M | 32M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($41M) | ($27M) | ($26M) | ($24M) | ($22M) | ($27M) | ($19M) | ($20M) |
| Operating Margin % | — | — | — | — | — | — | -8382.9% | — |
| Net Income | ($37M) | ($24M) | ($22M) | ($22M) | ($19M) | ($24M) | ($16M) | ($18M) |
| Net Margin % | — | — | — | — | — | — | -7020.7% | — |
| EBITDA | ($41M) | ($23M) | ($22M) | ($22M) | ($19M) | ($24M) | ($16M) | ($18M) |
| Earnings Per Share (EPS) | $-0.78 | $-0.50 | $-0.60 | $-0.63 | $-0.58 | $-0.71 | $-0.47 | $-0.54 |
| Shares Outstanding (M) | 48M | 47M | 37M | 34M | 33M | 33M | 33M | 33M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($83M) | ($80M) | ($55M) | ($32M) | ($23M) |
| Capital Expenditures (CapEx) | $3M | $2M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($85M) | ($82M) | ($56M) | ($32M) | ($24M) |
| FCF Margin % | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($23M) | ($20M) | ($18M) | ($22M) | ($17M) | ($23M) | ($16M) | ($15M) |
| Capital Expenditures (CapEx) | $1M | $0M | $1M | $0M | $1M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($24M) | ($21M) | ($19M) | ($22M) | ($18M) | ($23M) | ($16M) | ($15M) |
| FCF Margin % | — | — | — | — | — | — | -7265.3% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets | $436M | $385M | $269M | $84M | $45M |
| Cash & Cash Equivalents | $54M | $75M | $49M | $31M | $24M |
| Total Liabilities | $26M | $16M | $11M | $157M | $88M |
| Total Debt (Short + Long-Term) | $1M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $410M | $369M | $257M | ($72M) | ($43M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MBX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms